Table 1.
Patient characteristics (total of 124 patients)
| Characteristics | Frequency, n (%) |
|---|---|
| Age, mean ± SD, years | 59.4 ± 13.7 |
| > 60 years | 66 (53.2) |
| Men | 91 (73.4) |
| Smoking (out of 98 patients) | 76 (77.6) |
| ECOG-PS | |
| 0 | 63 (50.8) |
| 1 | 46 (37.1) |
| 2 | 15 (12.1) |
| Primary tumor location | |
| Larynx | 43 (34.7) |
| Oral cavity | 36 (29) |
| Hypopharynx | 23 (18.5) |
| Oropharynx | 10 (8.1) |
| Paranasal sinus | 7 (5.6) |
| Others | 5 (4) |
| Histological diagnosis | |
| Squamous cell carcinoma | 121 (97.6) |
| Others | 3 (2.4) |
| p16 positivity (out of 55 patients) | 13 (23.6) |
| PD-L1 positivity (out of 33 patients) | 17 (51.5) |
| Metastasis sites | |
| Lung | 57 (46) |
| Bone | 32 (25.8) |
| Soft tissue | 27 (21.8) |
| Liver | 20 (16.1) |
| Brain | 4 (3.2) |
| Others | 10 (8.1) |
| Previous treatments | |
| Chemoradiation | 87 (70.2) |
| Surgery | 62 (50) |
| Adjuvant | 48 (38.7) |
| Induction | 30 (24.2) |
| No. of previous lines | |
| 1 | 54 (43.5) |
| 2 | 35 (28.2) |
| ≥ 3 | 35 (28.2) |
| Nivolumab dose, median (min–max), mg | 200 (100–240) |
| Number of cycles, median (min–max) | 6 (3–80) |
| Cycle interval | |
| 14 days | 104 (83.9) |
| 21 days | 20 (16.1) |
| Concomitant radiotherapy | 18 (14.5) |
| NLR, median (min–max) | 3.6 (0.8–19.2) |
ECOG-PS Eastern Cooperative Oncology Group-Performance Status, NLR neutrophil-to-lymphocyte ratio, SD standard deviation